AbbVie Reports First-Quarter 2024 Financial Results

Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These...

Related Keywords

United States ,American ,Alphagan Combigan ,Roberta Michael ,Linzess Constella ,Lumigan Ganfort ,Richarda Gonzalez ,Landos Biopharma ,Tentarix Biotherapeutics ,Drug Administration ,American Academy Of Neurology ,Twitter ,Allergan ,European Medicines Agency ,Colitis Organisation ,American Academy Of Dermatology ,Boehringer Ingelheim ,Abbvie Inc ,Exchange Commission ,Reports First Quarter Diluted ,Adjusted Diluted ,These Results Include ,Unfavorable Impact ,Share Related ,First Quarter Net Revenues ,Reported Basis ,Quarter Global Net Revenues ,Immunology Portfolio Were ,Operational Basis ,Humira Biosimilar Competition ,Global Humira Net Revenues Were ,Global Skyrizi Net Revenues Were ,Global Rinvoq Net Revenues Were ,Oncology Portfolio Were ,Global Imbruvica Net Revenues Were ,Global Venclexta Net Revenues Were ,Neuroscience Portfolio Were ,Global Botox Therapeutic Net Revenues Were ,Global Vraylar Net Revenues Were ,Combined Global Ubrelvy ,Qulipta Net Revenues Were ,Aesthetics Portfolio Were ,Global Botox Cosmetic Net Revenues Were ,Global Juvederm Net Revenues Were ,Completed Acquisition ,Flagship Cancer Therapy ,Milestones Expense Incurred During ,First Quarter ,Botox Therapeutic ,Botox Cosmetic ,Priority Review ,Biologics License Application ,Breakthrough Therapy Designation ,Eczema Area ,Severity Index ,Worst Pruritus Numerical Rating Scale ,European Crohn ,Annual Meeting ,Allergan Aesthetic ,Juvederm Voluma ,American Academy ,Allergan Aesthetics ,Investor Relations ,Private Securities Litigation Reform Act ,Cerevel Therapeutics ,Quarterly Reports ,Ended March ,